Which first-line treatment provides the best survival for patients with EGFR-mutated NSCLC?
29 Oct 2019
byStephen Padilla
According to the results of a systematic review and network meta-analysis, osimertinib and gefitinib plus pemetrexed-based chemotherapy appear to be the best first-line treatments, as shown by their most favourable progression-free (PFS) and overall survival (OS), for patients with advanced epidermal growth factor receptor (EGFR)-mutated nonsmall cell lung cancer (NSCLC).